PATH | VRL
Menu

Intussusception Following Rotavirus Vaccine Administration: Post-Marketing Surveillance in the National Immunization Program in Australia

This article, published in Vaccine, reports that surveillance conducted following routine rotavirus vaccination in Australia did not find an overall increase in intussusception with use of RotaTeq® (Merck & Co., Inc.) and Rotarix® (GlaxoSmithKline Biologicals), although researchers found evidence of an elevated risk of intussusception following the first dose of both vaccines. The authors conclude that larger population-based studies with linked databases will help provide more definitive evidence. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Buttery JP, Danchin MH, Lee KJ, et al.

Published: 2011

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Buttery JP, Danchin MH, Lee KJ, et al. Intussusception Following Rotavirus Vaccine Administration: Post-Marketing Surveillance in the National Immunization Program in Australia. Vaccine. 2011;29(16):3061-3066.

Resource types: Peer-reviewed journal

Diseases/vaccines: Rotavirus

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Oceania